

Renumathy Dhanasekaran

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1830250/renumathy-dhanasekaran-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

107
papers

14,839
citations

46
h-index

121
g-index

137
ext. papers

22,362
ext. citations

10.6
avg, IF

5.37
L-index

#	Paper	IF	Citations
107	Effects of Immunosuppressive Drugs on COVID-19 severity in Patients with Autoimmune Hepatitis. <i>Liver International</i> , 2021 ,	7.9	3
106	Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1469-1479.e19	6.9	67
105	Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC).. <i>Current Treatment Options in Gastroenterology</i> , 2021 , 19, 351-368	2.5	0
104	Hepatitis C and Hepatocellular Cancer: To Treat or Not to Treat. <i>Clinical Liver Disease</i> , 2021 , 17, 169-173	2.2	0
103	Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. <i>Hepatology</i> , 2021 , 73, 2099-2109	11.2	18
102	Spontaneous Regression of Hepatocellular Carcinoma: When the Immune System Stands Up to Cancer. <i>Hepatology</i> , 2021 , 73, 1611-1614	11.2	2
101	Roadmap to resuming care for liver diseases after coronavirus disease-2019. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 885-892	4	7
100	Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. <i>Journal of Hepatology</i> , 2021 , 74, 567-577	13.4	151
99	Socioeconomic Factors Contribute to the Higher Risk of COVID-19 in Racial and Ethnic Minorities With Chronic Liver Diseases. <i>Gastroenterology</i> , 2021 , 160, 1406-1409.e3	13.3	2
98	Posttransplant Outcomes in Older Patients With Hepatocellular Carcinoma Are Driven by Non-Hepatocellular Carcinoma Factors. <i>Liver Transplantation</i> , 2021 , 27, 684-698	4.5	1
97	Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers. <i>Hepatology</i> , 2021 , 73, 2342-2360	11.2	14
96	Deciphering Tumor Heterogeneity in Hepatocellular Carcinoma (HCC)-Multi-Omic and Singulomic Approaches. <i>Seminars in Liver Disease</i> , 2021 , 41, 9-18	7.3	5
95	Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. <i>Gastroenterology</i> , 2021 , 161, 1502-1512	13.3	3
94	The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. <i>Nature Reviews Clinical Oncology</i> , 2021 ,	19.4	23
93	Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. <i>Hepatology Communications</i> , 2021 , 5, 1972-1986	6	4
92	Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification. <i>Human Pathology</i> , 2021 , 119, 15-27	3.7	0
91	Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. <i>World Journal of Hepatology</i> , 2021 , 13, 1107-1121	3.4	0

90	Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation. <i>Hepatology Communications</i> , 2021 , 5, 516-525	6	2
89	Decline in Annual Mortality of Hepatitis C Virus-Related Hepatocellular Carcinoma in the United States, From 2009 to 2018. <i>Gastroenterology</i> , 2020 , 159, 1558-1560.e2	13.3	4
88	One world, one pandemic, many guidelines: management of liver diseases during COVID-19. <i>Gut</i> , 2020 , 69, 1369-1372	19.2	27
87	MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. <i>Nature Communications</i> , 2020 , 11, 2860	17.4	16
86	The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex. <i>Journal of Biological Chemistry</i> , 2020 , 295, 2698-2712	5.4	6
85	and cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. <i>ELife</i> , 2020 , 9,	8.9	17
84	High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. <i>Journal of Hepatology</i> , 2020 , 73, 705-708	13.4	144
83	MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC. <i>Molecular Therapy - Nucleic Acids</i> , 2020 , 21, 850-859	10.7	8
82	Genomic Landscape of HCC. <i>Current Hepatology Reports</i> , 2020 , 19, 448-461	1	6
81	Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-transplant Clinical Outcome. <i>Clinical Transplantation</i> , 2020 , 34, e14128	3.8	0
80	Liver Injury in Liver Transplant Recipients With Coronavirus Disease 2019 (COVID-19): U.S. Multicenter Experience. <i>Hepatology</i> , 2020 , 72, 1900-1911	11.2	36
79	Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 1008-1016	18.8	113
78	Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 974-983	6.9	12
77	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019 , 157, 1253-1263.e2	13.3	77
76	A Tale of Two Complications of Obesity: NASH and Hepatocellular Carcinoma. <i>Hepatology</i> , 2019 , 70, 1056-1058	11.7	17
75	Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. <i>Gastroenterology</i> , 2019 , 156, 1683-1692.e1	13.3	79
74	MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T-Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling. <i>Blood</i> , 2019 , 134, 730-730	2.2	
73	Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. <i>Gastroenterology</i> , 2019 , 156, 492-509	13.3	100

72	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. <i>Cell</i> , 2018 , 173, 400-416.e11	56.2	1072
71	Comprehensive Characterization of Cancer Driver Genes and Mutations. <i>Cell</i> , 2018 , 173, 371-385.e18	56.2	854
70	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. <i>Cell</i> , 2018 , 173, 291-304.e6	56.2	888
69	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. <i>Cell</i> , 2018 , 173, 386-399.e32	56.2	133
68	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. <i>Cell</i> , 2018 , 173, 305-320.e10	56.2	166
67	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , 2018 , 173, 338-354.e15	56.2	560
66	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , 2018 , 173, 321-337.e10	56.2	1124
65	Pathogenic Germline Variants in 10,389 Adult Cancers. <i>Cell</i> , 2018 , 173, 355-370.e14	56.2	342
64	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. <i>Cell Reports</i> , 2018 , 23, 282-296.e4	10.6	188
63	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. <i>Cell Reports</i> , 2018 , 23, 227-238.e3	10.6	235
62	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018 , 23, 194-212.e6	10.6	146
61	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. <i>Cell Reports</i> , 2018 , 23, 297-312.e12	10.6	147
60	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018 , 23, 313-326.e5	10.6	295
59	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. <i>Cell Reports</i> , 2018 , 23, 181-193.e7	10.6	366
58	The Immune Landscape of Cancer. <i>Immunity</i> , 2018 , 48, 812-830.e14	32.3	1754
57	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. <i>Cell Reports</i> , 2018 , 23, 172-180.e3	10.6	66
56	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. <i>Cell Reports</i> , 2018 , 23, 213-226.e3	10.6	56
55	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. <i>Cell Reports</i> , 2018 , 23, 239-254.e6	10.6	405

54	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. <i>Cell Reports</i> , 2018 , 23, 255-269.e4	10.6	112
53	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. <i>Cell Reports</i> , 2018 , 23, 270-281.e3	10.6	121
52	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. <i>Cell Systems</i> , 2018 , 6, 271-281.e7	10.6	320
51	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. <i>Cell Systems</i> , 2018 , 6, 282-300.e2	10.6	159
50	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. <i>Cancer Cell</i> , 2018 , 33, 706-720.e9	24.3	275
49	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , 2018 , 33, 676-689.e3	24.3	377
48	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. <i>Cancer Cell</i> , 2018 , 33, 721-735.e8	24.3	228
47	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , 2018 , 33, 690-705.e9	24.3	277
46	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. <i>Cancer Cell</i> , 2018 , 34, 211-224.e6	24.3	327
45	MYC Functions As a Master Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies. <i>Blood</i> , 2018 , 132, 2619-2619	2.2	1
44	YAP-associated chromosomal instability and cholangiocarcinoma in mice. <i>Oncotarget</i> , 2018 , 9, 5892-5905.3	5.3	30
43	Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/ β -catenin-induced FGF18 expression in hepatocellular carcinoma. <i>Oncogene</i> , 2018 , 37, 1220-1236	9.2	28
42	Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC). <i>Oncotarget</i> , 2018 , 9, 5517-5528	3.3	26
41	Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma 2018 , 6, 125		32
40	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. <i>Cell Systems</i> , 2018 , 7, 422-437.e7	10.6	85
39	Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. <i>Cell Reports</i> , 2018 , 25, 1304-1317.e5	10.6	152
38	Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017 , 40, 27-34	2.7	33
37	Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2017 , 40, 410-420	2.7	9

36	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. <i>Cell</i> , 2017 , 169, 1327-1341.e23	56.2	1125
35	Management of Immunosuppression in Liver Transplantation. <i>Clinics in Liver Disease</i> , 2017 , 21, 337-353	4.6	14
34	The Liver in Oncology. <i>Clinics in Liver Disease</i> , 2017 , 21, 697-707	4.6	4
33	Transcriptional Induction of Periostin by a Sulfatase 2-TGF β -SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2017 , 77, 632-645	10.1	39
32	Clinical implications of basic research in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016 , 64, 736-45	5.4	31
31	Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. <i>F1000Research</i> , 2016 , 5,	3.6	104
30	Primary Carcinoma of the Liver 2016 , 574-581		
29	Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. <i>Current Gastroenterology Reports</i> , 2015 , 17, 34	5	5
28	Activation of the transforming growth factor- β /SMAD transcriptional pathway underlies a novel tumor-promoting role of sulfatase 1 in hepatocellular carcinoma. <i>Hepatology</i> , 2015 , 61, 1269-83	11.2	38
27	Vasodilator-stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11-dependent plasma membrane targeting of transforming growth factor beta receptors. <i>Hepatology</i> , 2015 , 61, 361-74	11.2	49
26	Response to Fibrosis progression in patients treated for hepatitis C recurrence. <i>Liver International</i> , 2015 , 35, 2625	7.9	
25	Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. <i>Liver International</i> , 2015 , 35, 2433-41	7.9	22
24	Liver Transplantation for Hepatocellular Carcinoma. <i>Current Transplantation Reports</i> , 2014 , 1, 215-223	1.5	
23	Challenges of recurrent hepatitis C in the liver transplant patient. <i>World Journal of Gastroenterology</i> , 2014 , 20, 3391-400	5.6	6
22	Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2013 , 24, 307-14	11.4	57
21	Hepatic preservation injury: severity of hepatitis C recurrence and survival after liver transplantation. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 1403-9	4	1
20	Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. <i>Oncology Reports</i> , 2013 , 29, 1259-67	3.5	85
19	Chinese skullcap in move free arthritis supplement causes drug induced liver injury and pulmonary infiltrates. <i>Case Reports in Hepatology</i> , 2013 , 2013, 965092	0.9	15

18	Response to Houlihan et al. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1807	0.7	1
17	Chemoembolization Combined with RFA for HCC:Survival Benefits and Tumor Treatment Response. <i>Journal of Cancer Therapy</i> , 2013 , 04, 493-499	0.2	3
16	Incidentally Discovered HCC (iHCC) in Explant Liver-Histopathologic Features and Clinical Outcome. <i>Journal of Cancer Therapy</i> , 2013 , 04, 394-398	0.2	1
15	Predictors of early mortality post transjugular intrahepatic portosystemic shunts and the role of hepatic venous pressure gradient. <i>Gastrointestinal Intervention</i> , 2012 , 1, 63-68		5
14	Influence of transjugular intrahepatic portosystemic shunt in patients awaiting orthotopic liver transplant on post-transplant outcome. <i>Gastrointestinal Intervention</i> , 2012 , 1, 69-73		3
13	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2012 , 23, 943-8	2.4	20
12	Liver test results do not identify liver disease in adults with α 1-antitrypsin deficiency. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 1278-83	6.9	35
11	Tumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapy. <i>Pathology Research and Practice</i> , 2012 , 208, 15-21	3.4	9
10	Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012 , 35, 345-50	2.7	13
9	Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. <i>Hepatic Medicine: Evidence and Research</i> , 2012 , 4, 19-37	3.4	151
8	Rare case of adult undifferentiated (embryonal) sarcoma of the liver treated with liver transplantation: excellent long-term survival. <i>Case Reports in Hepatology</i> , 2012 , 2012, 519741	0.9	7
7	Emerging Therapies for Hepatocellular Carcinoma 2012 , 263-290		
6	890 ALT ABNORMALITIES IN ADULTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY. <i>Journal of Hepatology</i> , 2011 , 54, S354	13.4	2
5	Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. <i>Hpb</i> , 2010 , 12, 174-80	3.8	39
4	Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. <i>American Journal of Gastroenterology</i> , 2010 , 105, 635-41	0.7	88
3	The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2010 , 21, 1197-204; quiz 204	2.4	14
2	Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC). <i>Journal of Surgical Oncology</i> , 2010 , 101, 476-80	2.8	163
1	MYC Functions as a Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies		1

